1 October 2023 false No description of principal activity Taxfiler 2024.6 09758105business:PrivateLimitedCompanyLtd2023-10-012024-09-30 097581052023-09-30 097581052023-10-012024-09-30 09758105business:AuditExemptWithAccountantsReport2023-10-012024-09-30 09758105business:FilletedAccounts2023-10-012024-09-30 097581052024-09-30 09758105business:Director12023-10-012024-09-30 09758105business:RegisteredOffice2023-10-012024-09-30 097581052023-09-30 09758105core:WithinOneYear2024-09-30 09758105core:WithinOneYear2023-09-30 09758105core:ShareCapitalcore:PreviouslyStatedAmount2024-09-30 09758105core:ShareCapitalcore:PreviouslyStatedAmount2023-09-30 09758105core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-09-30 09758105core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-09-30 09758105core:PreviouslyStatedAmount2024-09-30 09758105core:PreviouslyStatedAmount2023-09-30 09758105business:SmallEntities2023-10-012024-09-30 09758105countries:EnglandWales2023-10-012024-09-30 09758105business:OrdinaryShareClass12023-10-012024-09-30 09758105business:OrdinaryShareClass12022-10-012023-09-30 097581052022-10-012023-09-30 iso4217:GBP xbrli:shares xbrli:pure
Company Registration No. 09758105 (England and Wales)
VORTEX PHARMA SOLUTIONS LIMITED Unaudited accounts for the year ended 30 September 2024
VORTEX PHARMA SOLUTIONS LIMITED Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
VORTEX PHARMA SOLUTIONS LIMITED Company Information for the year ended 30 September 2024
Director
Tatiana PROKAEVA
Company Number
09758105 (England and Wales)
Registered Office
Centurion House London Road Stains-Upon-Thames TW18 4AX United Kingdom
Accountants
BNA Consulting Services Ltd One Kingdom Street Paddington Central London W2 6BD
- 3 -
VORTEX PHARMA SOLUTIONS LIMITED Statement of financial position as at 30 September 2024
2024 
2023 
Notes
£ 
£ 
Current assets
Inventories
142,950 
50,000 
Debtors
4
16,928 
6,295 
Cash at bank and in hand
49,766 
121,742 
209,644 
178,037 
Creditors: amounts falling due within one year
5
(33,532)
(19,375)
Net current assets
176,112 
158,662 
Net assets
176,112 
158,662 
Capital and reserves
Called up share capital
6
1 
1 
Profit and loss account
176,111 
158,661 
Shareholders' funds
176,112 
158,662 
For the year ending 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 21 September 2025 and were signed on its behalf by
Tatiana PROKAEVA Director Company Registration No. 09758105
- 4 -
VORTEX PHARMA SOLUTIONS LIMITED Notes to the Accounts for the year ended 30 September 2024
1
Statutory information
VORTEX PHARMA SOLUTIONS LIMITED is a private company, limited by shares, registered in England and Wales, registration number 09758105. The registered office is Centurion House , London Road, Stains-Upon-Thames, TW18 4AX, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the sale of goods is recognised when goods have been delivered to customers such that risks and rewards of ownership have transferred to them. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Inventories
Inventories have been valued at the lower of cost and estimated selling price less costs to complete and sell. In respect of work in progress and finished goods, cost includes a relevant proportion of overheads according to the stage of manufacturing/completion.
Financial instruments
The company has elected to apply the provisions of section 11 ' Basic Financial Instruments' and section 12 'Other Financial Instruments issues' of FRS 102 to all of its financial instruments. Basic financial assets, which includes debtors, cash and bank balances, are initially measured a transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement consists a financing transaction, where the transaction is measured at the present valve of the future receipts discounted at market rate of interest. Financial assets classified as receivable within one year are not amortised. Basic financial liabilities, including creditors are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Cash and cash equivalents
Cash at bank and in hand are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
- 5 -
VORTEX PHARMA SOLUTIONS LIMITED Notes to the Accounts for the year ended 30 September 2024
Taxation
The tax expenses represents the sum of the tax currently payable. The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further includes items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred taxation
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the company's accounts. Deferred tax is provided in full on timing differences which result in an obligation to pay more (or less) tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.
4
Debtors
2024 
2023 
£ 
£ 
Amounts falling due within one year
VAT
330 
224 
Other debtors
16,598 
6,071 
16,928 
6,295 
5
Creditors: amounts falling due within one year
2024 
2023 
£ 
£ 
Taxes and social security
4,093 
4,232 
Other creditors
8,201 
- 
Loans from directors
21,238 
15,143 
33,532 
19,375 
6
Share capital
2024 
2023 
£ 
£ 
Allotted, called up and fully paid:
1 Ordinary shares of £1 each
1 
1 
7
Average number of employees
During the year the average number of employees was 0 (2023: 0).
- 6 -